Ospemifene, vulvovaginal atrophy, and breast cancer.

@article{Wurz2013OspemifeneVA,
  title={Ospemifene, vulvovaginal atrophy, and breast cancer.},
  author={Gregory T. Wurz and Lin H Soe and Michael Degregorio},
  journal={Maturitas},
  year={2013},
  volume={74 3},
  pages={220-5}
}
The incidence and severity of vulvovaginal atrophy (VVA) in postmenopausal breast cancer patients has a significant impact on quality of life. While the etiology of VVA is primarily related to low estrogen levels seen in menopause, women with breast cancer have an added risk of VVA induced by a combination of chemotherapy, hormonal therapy, and menopause. Ospemifene is a new, non-hormonal selective estrogen receptor modulator (SERM) triphenylethylene derivative that is effective in treating VVA… CONTINUE READING